Twenty-five patients with metastatic breast cancer in progression after prior chemotheray ± hormonotherapy were treated with etoposide 50 mg/m2 i.v. days 1 to 5 every 21 days and mitomycin-C 10 mg/m2 i.v. day 1 every 42 days. A partial response (PR) occurred in 10 patients with an overall response rate of 40 % (47 % when only the 21 patients evaluable after 3 courses or more were considered). The median duration of PR was 10.5 months (range 3-31). The soft tissue metastatic sites were the most responsive. Toxicity was mild.
Get full access to this article
View all access options for this article.
References
1.
BuzdarA.U., TashimaC.K., BlumenscheimG.R., HortobagyiG.N., YapH.Y., KrutchikA.N., BodeyG.P., LivingstonR.B.: Mitomycin-C and Megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy. Cancer, 41: 392–395, 1978.
2.
De LenaM., JirilloA., BrambillaC., VillaS.: Mitomycin-C in metastatic breast cancer resistant to hormonotherapy and conventional chemotherapy. Tumori, 66: 481–487, 1980.
3.
DenefrioJ.M., EastD.R., TronerM.B., VogelG.R.: Phase II study of mitomycin-C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy. Cancer Treat. Rep., 62: 2113–2115, 1978.
4.
EderJ.P., AntmanK., PetersW., HennerW.D., EliasA., SheaT., SchryberS., AndersonJ., ComeS., SchnipperL., FreiE.III: High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J. Clin. Oncol., 4, 11: 1592–1597, 1986.
5.
EstevezR.A., CazapE.L., ChiesaG., ParisA.: Teniposide (VM26) plus mitomycin-C (M) in multitreated breast cancer adriamycin resistant patients. Proc. ASCO4: C287, March 1985.
6.
GarewaldH.S., BrooksR.J., JonesS.E., MillerT.P.: Treatment of advanced breast cancer with mitomycin-C combined with vinblastine or vindesine. J. Clin. Oncol., 1: 772–775, 1983.
7.
KonitsP.H., AisnerJ., Van EchoD.A., LichtenfeldK., WiernikP.H.: Mitomycin-C and vinblastine chemotherapy for advanced breast cancer. Cancer, 48: 1295–1298, 1981.
8.
LeghaS.S.: A review of mitomycin-C regimens in advanced breast cancer therapy. Clinical Therapeutics, Vol. 7, No. 3, 1985.
O'DweyrP.J., Leyland-JonesB., AlonsoM.T., MarsoniS., WittesR.E.: Etoposide (VP16-213). Current status of an active anticancer drug. N. Engl. J. Med., 312: 692–700, 1985.
11.
RadfordJ.A., KnightR.K., RubensR.D.: Mitomycin-C and vinblastine in the treatment of advanced breast cancer. Eur. J. Cancer Clin. Oncol., Vol. 21, No. 12, 1475–1477, 1985.
12.
Van OosteromA.T., PawlesT.J., HamersmaE., SmithI.E., EnglesmanE.: A phase II study of mitomycin-C in refractory advanced breast cancer. In: Breast Cancer: Experimental and Clinical Aspects. Eur. J. Cancer (Suppl.), 275–276, 1980.
13.
WHO Handbook for Reporting Results of Cancer Treatment.WHO, Geneva, 1979.
